HAE Earnings & Financial Statements
Haemonetics Corporation
$121.11
-$0.61(-0.50%)
82
Overall
80
Value
100
Tech
68
Quality
Market Cap
$5.54B
Volume
581.79K
52W Range
$48.55 - $121.19
Target Price
$124.36
HAE earnings and financial statements: Haemonetics Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
HAE Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.20M |
| Cost of revenue | $546.44M | $611.87M | $617.51M | $553.56M | $487.69M |
| Operating income | $156.73M | $221.82M | $164.88M | $156.03M | $80.75M |
| EBITDA | $178.32M | $238.87M | $249.08M | $251.31M | $181.90M |
| Net income | $97.31M | $167.68M | $117.56M | $115.40M | $43.38M |
| EPS (diluted) | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B |
| Total liabilities | $1.60B | $1.63B | $1.24B | $1.12B | $1.11B |
| Shareholders’ equity | $796.32M | $820.84M | $959.96M | $818.00M | $749.42M |
| Cash and equivalents | $245.44M | $306.76M | $178.80M | $284.47M | $259.50M |
| Long-term debt | $1.22B | $921.23M | $797.56M | $754.10M | $559.44M |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | $293.22M | $181.72M | $181.75M | $273.06M | $172.26M |
| Capital expenditure | -$31.41M | -$16.02M | -$38.13M | -$191.33M | -$96.51M |
| Free cash flow | $260.44M | $142.45M | $143.63M | $81.73M | $75.75M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HAE | $121.11 | -0.5% | 581.79K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |